Cargando…

Effect of Targeted Therapy With Pazopanib on Expression Levels of Transcription, Growth Factors and Components of AKT/m-TOR Signaling Pathway in Patients with Renal Cell Carcinoma

BACKGROUND: The effect of the targeted therapy on cancer molecular markers remains currently unknown. The aim of the study was to investigate the expression and content of transcription, growth factors and components of the AKT/m-TOR signaling pathway in kidney cancer patients before and after targe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spirina, Liudmila V, Usynin, Evgeny A, Yurmazov, Zahar A, Slonimskaya, Elena M, Kondakova, Irina V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773780/ https://www.ncbi.nlm.nih.gov/pubmed/29172268 http://dx.doi.org/10.22034/APJCP.2017.18.11.2977

Ejemplares similares

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy——AKT/m-TOR Pathway and Resistance to Cancer Therapy
por: SPIRINA, Liudmila V, et al.
Publicado: (2018)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway
por: Spirina, Liudmila V, et al.
Publicado: (2020)

Molecular Protein and Expression Profile in the Primary Tumors of Clear Cell Renal Carcinoma and Metastases
por: Spirina, Liudmila V., et al.
Publicado: (2020)

Transcription factors Brn-3α and TRIM16 in cancers, association with hormone reception
por: Spirina, Liudmila V., et al.
Publicado: (2019)

PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation
por: Spirina, Liudmila, et al.
Publicado: (2021)

The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary Thyroid Cancer
por: Spirina, Liudmila V., et al.
Publicado: (2021)

Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy
por: Yunusova, Natalia V, et al.
Publicado: (2016)

LC3B, mTOR, AMPK Are Molecular Targets for Neoadjuvant Chemotherapy in Gastric Cancers
por: Spirina, Liudmila V., et al.
Publicado: (2022)

Proteasome Functioning in Breast Cancer: Connection with Clinical-Pathological Factors
por: Shashova, Elena E., et al.
Publicado: (2014)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
por: Pick, Amy M., et al.
Publicado: (2013)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Autophagy-Related MicroRNA: Tumor miR-125b and Thyroid Cancers
por: Spirina, Liudmila V., et al.
Publicado: (2023)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
por: Wood, Christopher G., et al.
Publicado: (2020)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
por: Porta, Camillo, et al.
Publicado: (2017)

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017)

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
por: Harrison, Michael R.
Publicado: (2011)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

One year survivor of metastatic renal cell carcinoma treated with pazopanib
por: Inn, Fam Xeng, et al.
Publicado: (2017)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis
por: Spirina, Liudmila V, et al.
Publicado: (2022)

Tribbles homolog 3-mediated targeting the AKT/mTOR axis in mice with retinal degeneration
por: Saltykova, Irina V., et al.
Publicado: (2021)

Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer
por: Chen, Hongrun, et al.
Publicado: (2023)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
por: Jeon, So-Yeon, et al.
Publicado: (2019)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Estrogen Receptors and Ubiquitin Proteasome System: Mutual Regulation
por: Kondakova, Irina V., et al.
Publicado: (2020)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1qdkl7m44hqtthq54hkvgi53j5